Most of traditional anti-cancer drugs could not specifically target cancer cells because of the tumor mass usually composed of organized and heterogenetic types of cancer-associated cells. Cancer stem cells and tumor microenvironment play important roles on drug resistance, relapse and metastasis, which caused it difficult to treatment.
Through suppress cancer stem cell proliferation and block cell renew ability, also can suppress the cytokine secretion from cancer stem cells. This could destroy the tumor microenvironment, therefore suppresses the surrounding tumor growth.
The recurrent non-small cell lung cancer (NSCLC) patients only can be treated with a few drugs which market value is $ 5.6 billion.
- By the Company’s exclusive authorization from NTU, which identified CDX as the novel Lung cancer stem cells (LCSCs) markers, it also been identified can functionally promote the cancer stemness. Through anti-cancer stem cell drug platform screening, we identified SNS01 which target CDX.
- As an anti-cancer stem cell drug, SNS01 not only could suppress tumorous sphere formation and self-renewing, but also suppresses cytokine secreted from CSCs. In addition, CDX could regulate the expression of immune checkpoint PD-L1, which enable it to be combine with immune checkpoint inhibitors. The combination of SNS01 with immune checkpoint inhibitors (ICIs) may increase the response rate to ICIs by activating T cells, thus improve the caner treatment therapy.
- SNS01 will focus on target late- stage cancer, aims to prevent cancer recurrence and metastasis. Under this primes, it would get the license of Breakthrough Therapy Designation，BTD for FDA.